Company Sybleu Inc.

Equities

SYBE

US87114K1051

Pharmaceuticals

Delayed OTC Markets 03:59:37 2024-05-22 pm EDT 5-day change 1st Jan Change
0.0185 USD -25.25% Intraday chart for Sybleu Inc. -.--% -51.19%

Business Summary

SYBLEU Inc. is engaged in the acquisition, licensing and development of medical and veterinary applications. The Company is focused on developing therapies for human and animal health, medical devices, and clinical diagnostics. The Company is also developing drugs for treating cancer in companion animals and examining the role of artificial intelligence and machine learning in clinical diagnostics. It is also involved in the development of disposable medical devices. It has completed Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 99,402,492 91,842,702 ( 92.39 %) 0 92.39 %

Shareholders

NameEquities%Valuation
3,309,000 31.18 % 261 411 $
3,210,790 30.25 % 253 652 $
1,040,000 9.799 % 82 160 $

Company contact information

SYBLEU, Inc.

1034 Throgss Neck Expressway

10465, Bronx

+

address Sybleu Inc.(SYBE)